Duchenne Muscular Dystrophy
Clinical guidelines for managing progressive muscle weakness, reviewing dystrophin genetic mutations, and evaluating novel exon-skipping and gene therapies.
Table of Contents
🧠 Standard of Care & Symptoms
Duchenne Muscular Dystrophy (DMD) is a severe, X-linked recessive neuro-muscular disease characterized by progressive muscle degeneration and weakness.
- Presentation: Symptoms typically manifest in early childhood (ages 2 to 3) with motor delays, frequent falls, difficulty running or climbing stairs, a waddling gait, and **pseudohypertrophy** of the calf muscles (muscle tissue replaced by fat and fibrous tissue).
- Gowers' Sign: A classic clinical sign where the child must use their hands to "climb up" their own legs to stand upright, reflecting proximal lower-limb muscle weakness.
- Cardiorespiratory Decline: Progressive weakness eventually affects the diaphragm and cardiac muscle, leading to restrictive respiratory failure and dilated cardiomyopathy.
- Pathophysiology: Caused by out-of-frame mutations in the **DMD gene** on the X chromosome, preventing any functional synthesis of the **dystrophin protein**. Dystrophin acts as an essential mechanical link, anchoring the muscle cell's actin cytoskeleton to the extracellular matrix via the dystrophin-glycoprotein complex. Without it, muscle contractions cause membrane shearing, calcium influx, necrosis, and progressive fibrosis.
🧬 Genetic Diagnostics & Screening
Early identification is key to initiating protective therapies before extensive muscle tissue is replaced by fat and fibrosis.
- Serum Creatine Kinase (CK): A highly sensitive screening marker. Levels in infants with DMD are elevated 10 to 100 times the normal limit (often > 10,000 U/L) due to constant muscle cell damage.
- Genetic Testing: The gold standard. Confirms mutations (deletions, duplications, or point mutations) in the *DMD* gene. Identifying the exact mutation is critical for determining eligibility for mutation-specific therapies.
- Muscle Biopsy: Performed if genetic testing is inconclusive, demonstrating dystrophic changes (varying fiber size, necrotic fibers, fibrofatty replacement) and absent immunofluorescence staining for dystrophin.
💊 Corticosteroids & Care Guidelines
Standard pharmacological care focuses on slowing the rate of muscle degeneration and managing secondary systemic symptoms.
- Corticosteroids (Prednisone / Deflazacort): The cornerstone of DMD medical management. Daily administration of Prednisone (0.75 mg/kg) or Deflazacort (0.9 mg/kg) preserves muscle strength, prolongs independent ambulation by 2 to 3 years, and reduces the incidence of scoliosis and respiratory decline. Side effects (weight gain, Osteoporosis, behavioral changes, growth suppression) must be monitored closely.
- Cardiac Surveillance: Cardioprotective therapy utilizing **ACE Inhibitors** (e.g. Lisinopril) or **Beta-blockers** is initiated by age 10, or earlier if echocardiogram or cardiac MRI reveals ventricular dysfunction.
🧪 Exon-Skipping & Gene Therapies
Recent advances have introduced mutation-targeted therapies designed to restore partially functional dystrophin production.
- Exon-Skipping (Antisense Oligonucleotides): Weekly intravenous infusions designed to bind to pre-mRNA, skipping mutated exons and restoring the reading frame. This produces a shorter but partially functional dystrophin protein (converting a DMD phenotype to a milder Becker-like phenotype):
- Eteplirsen (Exondys 51): Targets mutations amenable to skipping exon 51.
- Golodirsen (Vyondys 53) & Viltolarsen (Viltepso): Target mutations amenable to skipping exon 53.
- Casimersen (Amondys 45): Targets mutations amenable to skipping exon 45.
- Gene Therapy (Delandistrogene moxeparvovec / Elevidys): An FDA-approved single-dose intravenous gene transfer therapy utilizing an adeno-associated virus (AAV) vector to deliver a transgene encoding a functional **micro-dystrophin** protein to muscle cells.
🔬 Biopsy & Histopathological Hallmarks
If a muscle biopsy (commonly of the vastus lateralis) is performed, standard H&E staining reveals key signs of ongoing muscle necrosis and repair:
- Myofiber Size Variation: Marked variation in muscle fiber diameter, showing mixed atrophy (shrunken fibers) and hypertrophy (abnormally enlarged compensatory fibers).
- Necrosis & Phagocytosis: Scattered necrotic muscle fibers undergoing digestion and removal by infiltrating macrophages (myophagocytosis).
- Regenerating Fibers: Small, immature regenerating muscle fibers, recognized by their basophilic cytoplasm and large, vesicular internal nuclei.
- Endomysial Fibrosis: The hallmark sign of disease progression. Progressive accumulation of endomysial collagen connective tissue and adipose tissue between individual muscle fibers, leading to loss of contraction elasticity.
🔬 Active Clinical Trials
Clinical trials are currently evaluating next-generation exon-skipping compounds with enhanced muscle cell penetration, gene editing tools (CRISPR/Cas9) to repair the DMD gene, and non-steroidal anti-inflammatory compounds.
A Phase III trial evaluating a novel peptide-conjugated PMO (P-PMO) designed to achieve superior muscle tissue delivery for exon 51 skipping.
Key Inclusion: Male, age 4 to 12, genetically confirmed DMD mutation amenable to exon 51 skipping, ambulatory (6-minute walk distance ≥ 300m), and on stable daily corticosteroid therapy for ≥ 6 months.Testing a non-steroidal anti-inflammatory and membrane-stabilizing compound to reduce muscle inflammation without steroid-like side effects.
Key Inclusion: Age ≥ 4, diagnosed with DMD, currently not on corticosteroids or experiencing severe side effects requiring corticosteroid discontinuation.A long-term study evaluating the safety and micro-dystrophin expression durability of gene therapy in ambulatory pediatric patients.
Key Inclusion: Age 4 to 7, ambulatory, genetically confirmed out-of-frame DMD mutation, negative for AAVrh74 neutralizing antibodies, and stable cardiac function.🗺️ Next Steps After Diagnosis
If a family member has recently been diagnosed with Duchenne Muscular Dystrophy, initiate these care coordination steps:
- Establish a Multidisciplinary Care Team: Coordinate with a pediatric neurologist, geneticist, physical therapist, pediatric cardiologist, pulmonologist, and orthopedist.
- Begin Physical Therapy Assessment: Initiate gentle stretching and range-of-motion exercises early. Avoid eccentric muscle exercises (such as downhill running or deep squats), which accelerate muscle fiber injury.
- Assess Pulmonary and Cardiac Baseline: Obtain a baseline echocardiogram and pulmonary function tests (PFTs) by age 5 to establish a cardiorespiratory baseline.
- Connect with Advocacy Networks: Join organizations like Parent Project Muscular Dystrophy (PPMD) and the Muscular Dystrophy Association (MDA) to access support, education, and trial resources.
❓ Patient FAQ
Q: Why does Duchenne Muscular Dystrophy primarily affect boys?
A: The DMD gene is located on the X chromosome. Females have two X chromosomes, so if one carries a mutation, the other normal X chromosome usually produces sufficient dystrophin. Males have only one X chromosome, so inheriting a mutated DMD gene causes the disease. Females carrying the mutation (carriers) are usually asymptomatic but can sometimes experience mild muscle weakness or cardiomyopathy.
Q: What is the difference between Duchenne and Becker muscular dystrophy?
A: Duchenne muscular dystrophy is caused by "out-of-frame" mutations, resulting in a complete absence of dystrophin and severe symptoms. Becker muscular dystrophy (BMD) is caused by "in-frame" mutations, allowing the production of a shortened, partially functional dystrophin protein, leading to a much milder, slower-progressing disease.
Get the Free 2026 Clinical AI Directory
Email us at caleb@openphr.org to receive our exclusive directory of over 150 open-source models and clinical trial databases.